|View printer-friendly version|
Charles River Laboratories’ Industry Experts to Present Advanced Modalities at Neuroscience 2023
“Neuroscience is one of the most complex areas of drug discovery,”
Highlighting Scientific Leadership
Throughout the conference, Charles River experts will present posters and host discussions on the latest developments in neuroscience research and innovative approaches to tackling neurodegenerative disorders. Posters are being presented on a range of topics, including phenotypic screening and cell models, the utilization of artificial intelligence (AI) and machine learning (ML) in preclinical imaging, and research into Huntington’s disease.
Dose-dependent Modulation of brain activity by Psilocybin in mice: Insights from Functional Ultrasound Imaging (Presented by
Susanne Back: Sunday, November 12, 9:00-10:00 AM EST)
Improved Kinematic Gait Phenotype in hDMDdel52/mdx mouse model of Duchenne Muscular Dystrophy after Treatment with Antisense Oligonucleotide BMN351 (Presented by
Jussi Rytkonen: Sunday, November 12, 1:00-2:00 PM EST)
Development of an ASO-based therapy targeting UBE3A for a patient with Dup15q Syndrome (Presented by Malika Bsibsi:
Monday, November 13, 1:00-2:00 PM EST)
Characterization of conditional Q175 (cQ175) and Q20 (cQ20) knockout models (Presented by
Susanne Back: Wednesday, November 15, 3:00-4:00 PM EST)
“For patients suffering with neurodegenerative disease, innovation in this field is critical,” said
Partnerships Driving Innovation in Neuroscience
Lastly, the increased use of AI/ML in drug discovery has allowed medicinal chemists to operate at a vastly different scale than traditional approaches, by enabling them to search much larger universes of potential compounds. In 2022,
A full schedule of Charles River’s activities during Neuroscience 2023 is available online. Additionally, experts will be available at Booth #1717 for meetings with those interested in discussing neuroscience research and drug discovery.
About Charles River
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.
Corporate Vice President, Investor Relations
Corporate Vice President, Public Relations